Small German start-up develops bluetongue virus vaccine within a few months
Verovaccines leverages its new capabilities for rapid emergency response and cost-effective classical animal health vaccine development
The German vaccine specialist Verovaccines has shown how to go from a simple BTV-3 virus sequence to a validated vaccine in just a few months. In addition, an approval dossier has been created, which is now around 90% complete. The company expects to receive emergency use authorization before the end of this year and thus bring an innovative BTV-3 vaccine to the market to combat the disease. In contrast to conventional virus-based vaccines, this new class of vaccine is generated from synthetic starting materials and is therefore virus-free. Your DIVA[1]capability supports effective outbreak control strategies.
The new development opportunities open up the possibility to rapidly develop further vaccines against other BTV serotypes. The concept of rapid response to emerging outbreaks is not expected to be limited to BTV, as the platform has been shown to be applicable to a variety of different pathogens. As part of the BTV-3 program, the platform has been extended by providing additional methods, procedures,
formulations and documentation. Due to the comprehensive nature of the platform, these elements can be used interchangeably between different vaccine programs. The result is cost- and time-efficient development, even for valuable classical vaccine programs with long-term sales potential.
Dr. Hanjo Hennemann, CEO: "The rapid development of this BTV-3 vaccine clearly demonstrates the power of our comprehensive technology platform. We also intend to use the company's new development capacities together with partners in joint developments and to attract further investors". Prof. Dr. SvenErik Behrens (CSO): "This success would not have been possible without our great 12-person team and the fruitful collaboration with the Friedrich-Loeffler-Institut, which operates the national BTV reference laboratory in Germany"
[1] DIVA (Differentiation of Infected from Vaccinated Animals) enables the differentiation of pathogen spread and vaccination countermeasures through diagnostics. The use of vaccines that are not based on DIVA and are based on whole viruses makes such diagnostic approaches "blind" and therefore restricts outbreak strategies and animal trade.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
